Citi raises Hutchmed target citing GSK deal’s platform validation
Analyst notes from four banks moved healthcare-sector shares in separate sessions on Friday, with Hong Kong-listed Hutchmed rising the most after Citi linked a $1.295 billion licensing deal with GSK to the company’s pre-clinical cancer drug platform.
Citi analysts wrote that the Hutchmed-GSK deal — which excludes royalties on net sales — appears to validate a specific drug candidate platform ahead of clinical trials. The analysts raised their 2026–2028 oncology and immunology revenue estimates by 14% to 27%, and lifted the stock target to HK$39.00 from HK$36.00. Hutchmed shares were last up 3.3% at HK$22.60. The company has guided to 2026 oncology and immunology revenue of $330 million to $450 million.
In Tokyo, SMBC Nikko Securities analyst Shinnosuke Tokumoto raised Nakanishi to outperform from neutral, with a target price of ¥4,000, up from ¥3,300. The five-year operating-profit CAGR forecast was lifted to 16% from 13%. Tokumoto attributed the outlook to sustained U.S. market-share gains, replacement demand for pandemic-era purchases in Europe, Japan and the U.S., and new product sales targeting emerging markets. Nakanishi shares rose 2.95% to ¥3,135.
Berenberg analysts said AstraZeneca’s experimental chronic obstructive pulmonary disease drug tozorakimab could become a market leader if it proves effective across all patient groups. The analysts noted that initial trial results released by the U.K. drugmaker earlier this year showed benefits both in the primary population of former smokers and in the overall population, and across stages of lung function. They compared the drug to similar compounds from Roche and Sanofi, which delivered mixed results in trials last year, and said AstraZeneca’s candidate is expected to work across a broader cohort of COPD patients. “We would view 30% exacerbation reduction to be a highly positive result and ahead of expectations,” Berenberg wrote. AstraZeneca shares rose 1.5%.
J.P. Morgan analysts wrote that Bayer’s agricultural division is on track to hit 2029 targets set a couple of years ago, but that the market isn’t fully grasping the unit’s potential. At a Wednesday event, the German conglomerate reiterated its 2029 forecast for the agricultural division — incremental sales of 3.5 billion euros over the 2024–29 period and an improvement in underlying Ebitda margin to the mid-20s percentage range. According to JPM, consensus estimates for 2029 sales and underlying Ebitda fall short of what Bayer’s guidance implies by 3% and 9%, respectively. Bayer shares fell 0.5%.
The four notes reflect the breadth of investor attention on healthcare, from licensing deals and clinical-trial benchmarks to multi-year division forecasts and product-cycle dynamics.